{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:39:06Z","timestamp":1777934346893,"version":"3.51.4"},"reference-count":7,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Bevacizumab is a human monoclonal antibody against VEGF. Many adverse reactions about bevacizumab are identified including venous and arterial thromboembolism, nausea, fatigue, alopecia, proteinuria, gastrointestinal system (GIS) perforation, exfoliative dermatitis, and peripheral edema and thrombocytopenia. In this paper, we report a case of bevacizumab-induced dose-dependent, toxicity-mediated drug-induced thrombotic microangiopathy.<\/jats:p>","DOI":"10.1177\/1078155218800371","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T03:34:45Z","timestamp":1537932885000},"page":"1754-1757","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["A severe case of bevacizumab-induced thrombotic microangiopathy"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9614-2801","authenticated-orcid":false,"given":"Mert","family":"Bektas","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Istanbul University Cerrahpa\u015fa Medical Faculty Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilay S","family":"Samanc\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul University Cerrahpa\u015fa Medical Faculty Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simay","family":"Cokgezer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Istanbul University Cerrahpa\u015fa Medical Faculty Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Keskin","sequence":"additional","affiliation":[{"name":"Department of Haematology, Istanbul University Cerrahpa\u015fa Medical Faculty Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuat H","family":"Demirelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul University Cerrahpa\u015fa Medical Faculty Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,9,26]]},"reference":[{"key":"bibr1-1078155218800371","doi-asserted-by":"crossref","unstructured":"Vakiti A, Singh D, Pilla R, et\u00a0al. Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab.\n                      J Oncol Pharm Pract\n                      2018. [Epub ahead of print].","DOI":"10.1177\/1078155218774895"},{"key":"bibr2-1078155218800371","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1312353"},{"key":"bibr3-1078155218800371","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2018.02.003"},{"key":"bibr4-1078155218800371","doi-asserted-by":"crossref","unstructured":"George JN and Nester C. Syndromes of thrombotic microangiopathy.\n                      N Engl J Med\n                      2014; 371(19): 1847\u20138.","DOI":"10.1056\/NEJMc1410951"},{"key":"bibr5-1078155218800371","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21470"},{"key":"bibr6-1078155218800371","doi-asserted-by":"crossref","unstructured":"Scully M, Cataland S, Coppo P, et\u00a0al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.\n                      J Thromb Haemost\n                      2017; 15(2): 312\u2013322.","DOI":"10.1111\/jth.13571"},{"key":"bibr7-1078155218800371","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1376153"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155218800371","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155218800371","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155218800371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:19:59Z","timestamp":1777688399000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155218800371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,26]]},"references-count":7,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1177\/1078155218800371"],"URL":"https:\/\/doi.org\/10.1177\/1078155218800371","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,26]]}}}